{"entity":{"id":"nct02180724","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","aka":[],"tldr":"A phase 2 trial of Acalabrutinib in waldenström macroglobulinaemia, run by Acerta Pharma BV, active and no longer recruiting.","summary":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia is a phase 2 interventional study registered as NCT02180724 by Acerta Pharma BV, with 107 participants enrolled, started 2014-09-11 and due to reach its primary completion in 2019-10-01. Interventions recorded: Acalabrutinib (ACP-196). Results have been posted on the registry.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02180724","url":"https://clinicaltrials.gov/study/NCT02180724"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["waldenstrom"],"sections":[],"technologies":[],"targets":[],"drugs":["acalabrutinib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02180724","phase":"2","setting":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","sponsor":"Acerta Pharma BV","enrolled":107,"outcomes":[]},"route":"/trials/nct02180724/","neighbours":{"cancer":[{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}